Omnicell (NASDAQ:OMCL) Issues FY 2026 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.150-2.300 for the period, compared to the consensus EPS estimate of 1.810. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q3 2026 guidance to 0.350-0.430 EPS.

Omnicell Stock Down 4.7%

Shares of NASDAQ:OMCL opened at $35.37 on Friday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 42.11, a PEG ratio of 0.96 and a beta of 0.96. The firm’s 50-day simple moving average is $41.97 and its 200-day simple moving average is $41.09. The company has a quick ratio of 1.29, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. Omnicell has a fifty-two week low of $28.90 and a fifty-two week high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities research analysts predict that Omnicell will post 1.31 earnings per share for the current year.

Analyst Ratings Changes

OMCL has been the subject of a number of analyst reports. Craig Hallum reissued a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Zacks Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Wells Fargo & Company reduced their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday. Finally, KeyCorp decreased their target price on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Friday. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.43.

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. This trade represents a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.92% of the company’s stock.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported second-quarter adjusted EPS of $0.94, well above the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million and also exceeded estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year 2026 non-GAAP EPS outlook to $2.15–$2.30, above the roughly $1.81 analyst consensus, and lifted its full-year revenue outlook to $1.225–$1.245 billion. Demand for connected devices, technical services and SaaS offerings, along with cost controls and tariff refunds, supported results. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
• Positive Sentiment: Omnicell highlighted momentum in its Titan XT and OmniSphere platforms, pointing to pipeline growth and longer-term opportunities in medication-management automation. KeyCorp maintained an “overweight” rating, although it reduced its price target from $70 to $65. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. purchased a new stake in Omnicell during the 4th quarter worth about $306,000. Creative Planning lifted its holdings in Omnicell by 16.7% in the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after purchasing an additional 1,347 shares in the last quarter. Empowered Funds LLC purchased a new position in Omnicell in the 4th quarter valued at about $274,000. Magnetar Financial LLC acquired a new stake in shares of Omnicell during the 3rd quarter worth about $230,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Omnicell during the third quarter worth about $224,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.